| Product NDC: | 67457-268 |
| Proprietary Name: | Fludarabine Phosphate |
| Non Proprietary Name: | Fludarabine Phosphate |
| Active Ingredient(s): | 25 mg/mL & nbsp; Fludarabine Phosphate |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 67457-268 |
| Labeler Name: | Mylan Institutional LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA090724 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20130130 |
| Package NDC: | 67457-268-02 |
| Package Description: | 1 VIAL, GLASS in 1 CARTON (67457-268-02) > 2 mL in 1 VIAL, GLASS |
| NDC Code | 67457-268-02 |
| Proprietary Name | Fludarabine Phosphate |
| Package Description | 1 VIAL, GLASS in 1 CARTON (67457-268-02) > 2 mL in 1 VIAL, GLASS |
| Product NDC | 67457-268 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Fludarabine Phosphate |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20130130 |
| Marketing Category Name | ANDA |
| Labeler Name | Mylan Institutional LLC |
| Substance Name | FLUDARABINE PHOSPHATE |
| Strength Number | 25 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |